New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease

Authors

  • Darla R. Shores MD,

    1. Division of Pediatric Gastroenterology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • David G. Binion MD,

    1. Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Bruce A. Freeman PhD,

    1. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Paul R.S. Baker PhD

    Corresponding author
    1. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    • Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, E1340 Thomas E. Starzl Biomedical Sciences Tower, Pittsburgh, PA 15261
    Search for more papers by this author

Abstract

Dietary and endogenously modified lipids modulate inflammation by functioning as intra- and intercellular signaling molecules. Proinflammatory lipid mediators such as the eicosanoids compete against the signaling actions of newly discovered modified fatty acids that act to resolve inflammation. In inflammatory bowel disease, multiple aberrancies in lipid metabolism have been discovered, which shed further light on the pathogenesis of intestinal inflammation. Mechanisms by which lipids modulate inflammation, abnormalities of lipid metabolism in the setting of inflammatory bowel disease, and potential therapeutic application of lipid derivatives in this setting are discussed. (Inflamm Bowel Dis 2010)

Ancillary